Expert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung Cance

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:

• Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistance
• Performing biomarker testing on cytology vs surgical or anatomic pathology specimens
• Factors affecting turnaround time when testing liquid biopsy vs tissue specimens
• Choice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skipping
• Concordance between IHC and FISH or NGS for ALK rearrangements
• Use of fluid cytology specimens when testing for fusions in RET or NTRK and MET amplification
• Cost considerations with performing multiple single-gene assays vs upfront NGS
• Testing for driver mutations in early-stage NSCLC
• Developing institutional workflows to enable pathologists to order reflex molecular testing panels

Presenters:

Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
The Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Content supported by an educational grant from Lilly.

Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.